


In re Application of: Koichi ENDO, et al.
 Serial No.: 09/485,583
 Date: February 14, 2000
 FOR: THERAPEUTICS OF BONE...



Art Unit: 1617
 Confirmation No.:
 Examiner: K. STILLER
 Washington, D.C.
 Atty.'s Docket: ENDO=12
 Date: March 5, 2002

1617#
RECEIVED
 MAR 14 2002

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is an ☐ Amendment ☒ Response
 in the above-identified application.

- ☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
☐ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate		Additional Fee
Total		Minus		=		x 9	\$	x18	\$
Indep.		Minus		=		x42	\$	x84	\$
First Presentation of Multiple Dependent Claim						140	\$	+280	\$
T O T A L A D D I T I O N A L C L A I M S F E E							\$	Total	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

☒ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
☐ Second - \$200.00
☐ Third - \$460.00
☐ Fourth - \$720.00

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
☐ Second - \$ 400.00
☒ Third - \$ 920.00
☐ Fourth - \$1440.00

☐ Less fees (\$) already paid for months extension of time on .

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

☐ A check in the amount of \$ is attached (check no.).

☒ Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ 920.00 is attached.

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:
 Anne M. Kornbau
 Registration No. 25,884



RECEIVED
MAR 14 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: ENDO=12

In re Application of:)	Art Unit: 1617
)	
Koichi ENDO, et al.)	Examiner: K.STILLER
)	
Appln. No.: 09/485,583)	Washington, D.C.
)	
Filed: February 14, 2000)	March 5, 2002
)	
For: THERAPEUTICS OF BONE)	
RESORPTION-ASSOCIATED)	
DISEASES)	

RESPONSE

Honorable Commissioner for Patents
Washington, D.C. 20231

In response to the Office Action of
September 6, 2001, for which a three month extension of
time to respond is hereby requested, please enter the
following response:

REMARKS

It is noted that the restriction requirement has
been made final. Accordingly, claims 8-11 and 15-18 have
been examined. The Office Action of September 6, 2001, has
been carefully studied. It is believed that all of the
claims are allowable, and favorable action is earnestly
requested.

Claims 8-11 and 15-18 are rejected under 35
U.S.C. 103(a) as being unpatentable over "The
Pharmacological Basis of Therapeutics" in view of Hukkanen
et al. and Moore et al. The Examiner alleges that "The